dromlakhani Screen for central precocious puberty indication
STEP 1 — Gather Information
Collect history of hydrocephalus, intracranial tumors arising in or near the hypothalamic region (e.g., optic pathway glioma, craniopharyngioma), and details of cranial/spinal radiation therapy including fields involving the hypothalamic‑pituitary axis and dose if available.
STEP 2 — Rule In / Rule Out
If the survivor has any of the following: history of hydrocephalus, tumor in/near hypothalamus, or exposure to hypothalamic‑pituitary radiation → Rule in for CPP screening; otherwise → Rule out (no routine CPP screening indicated).
STEP 3 — Classify or Stratify
Classify as CPP screening indicated when any risk factor is present; no further stratification is required per guideline (all indicated survivors receive periodic assessment).
STEP 4 — Decide
For those indicated, initiate periodic clinical assessment every 6–12 months for signs of central precocious puberty (breast development in girls, testicular volume change in boys interpreted with serum testosterone and LH drawn before 10:00 AM) and refer to pediatric endocrinology if pubertal onset is suspected before age 8 years (girls) or 9 years (boys).
Clinical Guardrails / Mimics / Pitfalls
Do not rely on testicular volume alone to assess pubertal progression in males previously treated with gonadotoxic therapy, as it may be reduced independent of central puberty. Elevated LH or testosterone may reflect primary gonadal injury rather than central onset; interpret in the context of cancer history. Avoid mistaking early adrenarche or benign variants for CPP. Remember that CPP can coexist with growth hormone deficiency; assess growth velocity alongside pubertal staging.
Concrete Clinical Example
A 7‑year‑old female survivor of an optic pathway glioma treated with surgical resection and 24 Gy cranial radiation (no hydrocephalus) presents for follow‑up. History includes tumor near hypothalamus → CPP screening indicated. Clinician documents Tanner stage breast development every 6 months; at age 8 years breast bud appears, prompting LH/FSH and estradiol evaluation and referral for possible GnRH‑agonist therapy.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175